西格列汀与瑞格列奈治疗初诊2型糖尿病老年患者的效果比较
x

请在关注微信后,向客服人员索取文件

篇名: 西格列汀与瑞格列奈治疗初诊2型糖尿病老年患者的效果比较
TITLE:
摘要: 目的:比较西格列汀与瑞格列奈治疗初诊2型糖尿病老年患者的临床疗效及安全性。方法:选取初诊2型糖尿病老年患者214例,按随机数字表法分为研究组和对照组,各107例。两组患者均给予正规的糖尿病饮食,进行健康教育及适当运动锻炼。对照组患者口服瑞格列奈片1.0 mg,tid;研究组患者口服西格列汀片100 mg,qd。两组患者均治疗12周。观察两组患者治疗前后实验室检查指标及空腹血糖(FBG)、餐后血糖(PBG)、糖化血红蛋白(HbA1c)水平及体质量指数(BMI),并比较不良反应发生情况。结果:两组患者治疗前后实验室检查指标比较,差异无统计学意义(P>0.05)。两组患者治疗后FBG、PBG、HbA1c显著降低,差异有统计学意义(P<0.05),但组间比较,差异无统计学意义(P>0.05)。两组患者治疗后BMI显著升高,且对照组高于研究组,差异有统计学意义(P<0.05)。研究组患者无低血糖发生,对照组患者中有3例发生低血糖,两组比较差异有统计学意义(P<0.05)。结论:西格列汀与瑞格列奈疗效相当,均可有效降低初诊2型糖尿病老年患者的血糖,且低血糖的发生率较低,安全性较好,但西格列汀对患者BMI控制较好。
ABSTRACT: OBJECTIVE: To comparison the clinical efficacy and safety of sitagliptin and Repaglinide in the treatment of newly diagnosed patients with type 2 diabetes mellitus. METHODS: 214 newly diagnosed patients with type 2 diabetes mellitus were randomly divided into study group and control group with 107 cases in each group according to random number table method. Both group received routine diabetes diet, health education and suitable exercise. Control group was treated with Repaglinide tablet 1.0 mg, tid; while study group was treat with Sitagliptin tablet 100 mg, qd. Lab indexes, FBG, PBG, HbA1c and BMI were observed in 2 groups before and after treatment. ADR were compared between 2 groups. RESULTS: There was no statistical significance in lab indexes between 2 groups before and after treatment (P>0.05). After treatment, FBG, PBG, HbA1c were significantly decreased significantly in 2 groups, with statistical significance (P<0.05), there was no statistical significance between 2 groups (P>0.05). BMI of 2 groups were increased significantly, and the study group was higher than the contrd group, with statistical sighificance (P<0.05). Patients in the study group had no hypoglycemia, while 3 patients in the control group suffered from it, there was statistical significance (P>0.05). CONCLUSIONS: Sitagliptin is similar with repaglinide in therapeutic efficacy; both can effectively reduce blood glucose of elderly patients with newly diagnosed type 2 diabetes mellitus, and the incidence of hypoglycemia was low, the saterty was good, but sitagliptin has a better control of BMI in patients.
期刊: 2016年第27卷第26期
作者: 陈军,甘华葵,孙毅
AUTHORS: CHEN Jun,GAN Huakui,SUN Yi
关键字: 初诊;老年;2型糖尿病;西格列汀;瑞格列奈
KEYWORDS: Newly diagnosed; Elderly; Type 2 diabetes mellitus; Sitagliptin; Repaglinide
阅读数: 761 次
本月下载数: 3 次

* 注:未经本站明确许可,任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作!